Search company, investor...

Executives

13

Board of Directors

3

RainDance Technologies Management Team

13 Team Members

RainDance Technologies has 13 executives. RainDance Technologies's current Chief Executive Officer is Kathy Ordonez.

Name

Work History

Title

Status

Kathy Ordonez

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Kathy Ordonez

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

RainDance Technologies Board of Directors

3 Board of directors

RainDance Technologies has 3 board of directors, including Jeff Samberg.

Name

Firm

Work History

Other Seats

Jeff Samberg

RainDance Technologies

Michael Hunkapiller

Michael Hunkapiller joined Alloy in 2004 after 30-year career in bioscience research and executive management in the life science industry. He focuses on investments in life science research tools and instrumentation, as well as clinical diagnostics.Operating experienceA renowned scientist, entrepreneur and life science industry executive, Mike brings a unique mix of experience to Alloy. He spent 21 years at Applied Biosystems (NASDAQ: LIFE), which he co-founded and helped grow from startup to almost $2 billion in annual revenues supplying instrument and reagent systems for life science research. At ABI, he held several positions, most recently president and general manager. He was also a founder of ABI's sister company Celera Genomics (NASDAQ: CRA) and senior vice president of Applera Corp. (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research, especially for his invention of the automated Gene and Protein Sequencer used to sequence the human genome. He was recently elected to the National Academy of Engineering for his life-long dedication to the human genome mapping project and the field of comparative genetics. He received a B.S. in Chemistry from Oklahoma Baptist University in 1970 and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech in 1974.Current board seatsMike serves on the board of directors of Codon Devices, Fluidigm, Pacific Biosciences, NuGEN, Artemis Health, and Raindance Technologies.

RainDance Technologies

Sherrill Neff

Quaker Partners manages venture capital and growth equity investments, with > $700 million-in-assets under management. Based in Philadelphia, PA. Quaker Partners has invested only in healthcare companies, primarily in the Mid-Atlantic Region. Sectors: Biopharmaceuticals, Medical Technology and Medical Devices, Clinical Diagnostics and Life Science Tools, Healthcare Services. Our funds are fully committed, and we are not making new investments at this time.

RainDance Technologies

Name

Jeff Samberg

Michael Hunkapiller

Sherrill Neff

Firm

Work History

Michael Hunkapiller joined Alloy in 2004 after 30-year career in bioscience research and executive management in the life science industry. He focuses on investments in life science research tools and instrumentation, as well as clinical diagnostics.Operating experienceA renowned scientist, entrepreneur and life science industry executive, Mike brings a unique mix of experience to Alloy. He spent 21 years at Applied Biosystems (NASDAQ: LIFE), which he co-founded and helped grow from startup to almost $2 billion in annual revenues supplying instrument and reagent systems for life science research. At ABI, he held several positions, most recently president and general manager. He was also a founder of ABI's sister company Celera Genomics (NASDAQ: CRA) and senior vice president of Applera Corp. (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research, especially for his invention of the automated Gene and Protein Sequencer used to sequence the human genome. He was recently elected to the National Academy of Engineering for his life-long dedication to the human genome mapping project and the field of comparative genetics. He received a B.S. in Chemistry from Oklahoma Baptist University in 1970 and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech in 1974.Current board seatsMike serves on the board of directors of Codon Devices, Fluidigm, Pacific Biosciences, NuGEN, Artemis Health, and Raindance Technologies.

Quaker Partners manages venture capital and growth equity investments, with > $700 million-in-assets under management. Based in Philadelphia, PA. Quaker Partners has invested only in healthcare companies, primarily in the Mid-Atlantic Region. Sectors: Biopharmaceuticals, Medical Technology and Medical Devices, Clinical Diagnostics and Life Science Tools, Healthcare Services. Our funds are fully committed, and we are not making new investments at this time.

Other Seats

RainDance Technologies

RainDance Technologies

RainDance Technologies

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare RainDance Technologies to Competitors

OncoTAB Logo
OncoTAB

OncoTAB is a biotechnology company focused on improving the quality of cancer care. The company's main offering is a non-invasive blood test that aids in the detection of breast cancer in women with dense breast tissue. OncoTAB primarily serves the healthcare industry. It is based in Charlotte, North Carolina.

Freenome Logo
Freenome

Freenome serves as a biotechnology company focused on early cancer detection through advanced diagnostic tools. The company develops blood tests that identify early signs of cancer by analyzing biomarkers from tumor and non-tumor sources using a multiomics platform. These tests are designed to be non-invasive and accessible, aiming to detect various types of cancer at its most treatable stages. It was founded in 2014 and is based in South San Francisco, California.

A
Accuragen

Accuragen is a company focused on the development of cancer diagnostics technology in the healthcare sector. The company's main service is the development of liquid biopsy technology, which is a non-invasive alternative to tissue biopsy, used for DNA and RNA sequencing to determine a patient's optimal treatment plan. Accuragen primarily sells to the healthcare industry, specifically in the field of cancer treatment. It is based in Menlo Park, California.

C
CirculoGene Diagnostics

CirculoGene Diagnostics is a molecular diagnostics company operating in the healthcare industry. The company offers a comprehensive blood-based approach to detecting clinically significant tumor DNA/RNA alterations, aiding oncologists in personalizing and monitoring patient treatment plans. Its services primarily cater to the healthcare and medical industry. CirculoGene Diagnostics was formerly known as CirculoGene Theranostics, LLC. It was founded in 2015 and is based in Birmingham, Alabama.

20/20 GeneSystems Logo
20/20 GeneSystems

20/20 GeneSystems is a company focused on modernizing clinical lab testing, primarily in the healthcare and biotechnology sectors. The company offers diagnostic tests that aid in the fight against cancer and COVID-19, utilizing machine learning and real-world data to provide comprehensive testing services. Their main offerings include a blood test that combines the results of multiple cancer biomarker tests to calculate a probability score for different types of cancers, and a range of COVID-19 testing services. It is based in Rockville, Maryland.

L
Liquid Genomics

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.